Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study
Public ClinicalTrials.gov record NCT00604383. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 3, Multicenter,Parallel,Randomized Dbl-masked,Placebo-controlled Study of the Effects of 32 mg/dy Ruboxistaurin Vision Loss in Patients With Type 1 or Type 2 Diabetes Mellitus and an Early Treatment Diabetic Retinopathy Study Level Between 47A and 53E.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is to test whether or not 32 milligrams (mg) of ruboxistaurin a day over three years will reduce vision loss associated with diabetic retinopathy.
Study identification
- NCT ID
- NCT00604383
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 685 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2001
- Primary completion
- May 31, 2005
- Completion
- May 31, 2005
- Last update posted
- Oct 5, 2016
2001 – 2005
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT -5 hours, EST) or speak with your personal physician. | Indianapolis | Indiana | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Diabetic Retinopathy trials
Other public records listing Diabetic Retinopathy. Sorted by last update posted; newest first. Not a recommendation.
- NCT05079399: Biomarker of Diabetic Retinopathy Recruiting
- NCT07588100: A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7663498 Following Intravitreal Administration in Participants With Diabetic Retinopathy Recruiting
- NCT07592273: Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema Recruiting
- NCT06257082: Video-based Patient Education Intervention for Diabetic Eye Screening in Latinx Communities Recruiting
- NCT06321302: A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy Active, not recruiting
- NCT06943599: Strategies for Improving Linkage-to-Care After Eye Disease Screening Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00604383, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 5, 2016 · Synced Sep 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00604383 live on ClinicalTrials.gov.